Summary & Overview
HCPCS Q0164: Prochlorperazine 5 mg Oral Anti-Emetic for Chemotherapy
HCPCS Level II code Q0164 denotes prochlorperazine maleate 5 mg oral, an FDA-approved anti-emetic authorized as a complete therapeutic substitute for an IV anti-emetic during chemotherapy for up to 48 hours. Nationally, this code matters because it captures use of an oral alternative to IV administration in oncology supportive care, affecting billing pathways, site-of-service decisions, and medication substitution policies in infusion settings.
Key payers included in the coverage discussion are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will learn how the code is used to represent an oral anti-emetic substitute in chemotherapy encounters, the typical clinical and service settings where it applies, and the types of operational considerations that influence billing and reimbursement. The publication provides benchmarks where available, notes on claim categorization and billing posture for infusion centers and outpatient oncology clinics, and the clinical context supporting substitution of oral prochlorperazine for IV anti-emetics during a 48-hour regimen.
Data not available in the input for specific payor coverage policies, utilization rates, or associated ICD-10 linkage is noted where applicable. The focus is on clarifying the code's clinical meaning, expected site-of-service, and relevance for national payers and oncology billing operations.
Billing Code Overview
HCPCS Level II code Q0164 describes prochlorperazine maleate, 5 mg, oral, an FDA-approved prescription anti-emetic intended for use as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, with a maximum regimen of 48 hours.
Service Type: Oral anti-emetic medication used as an IV substitute during chemotherapy
Typical Site of Service: Oncology clinic or outpatient chemotherapy infusion center, where the oral formulation is administered or dispensed to patients receiving chemotherapy as an alternative to IV anti-emetic therapy.
Clinical & Coding Specifications
Clinical Context
A patient receiving outpatient chemotherapy for solid tumor malignancy experiences nausea and vomiting risk around infusion time. The oncology nurse documents that the patient has a history of severe chemotherapy-induced nausea and cannot receive or declines an IV anti-emetic during the infusion. The prescriber orders an FDA‑approved oral prochlorperazine maleate regimen, Q0164 (prochlorperazine maleate, 5 mg, oral), to be administered as a complete therapeutic substitute for an IV anti-emetic, with dosing limited to a 48‑hour regimen. The medication is dispensed by the infusion center pharmacy or clinic dispenser and administered or given to the patient at the time of chemotherapy when IV administration is not feasible or contraindicated. Typical workflow steps: prescriber documents indication and rationale for oral substitute in the medical record; pharmacist verifies dosing and dispense limits; nurse documents administration or patient receipt of the package and monitors for efficacy and adverse effects during the 48‑hour window. Billing is submitted using Q0164 with an appropriate modifier reflecting the service circumstance and the patient’s insurer rules.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
11 | Routine services | Use when billing the routine administration/dispensing as part of the usual chemotherapy visit. |